Skip to content

Medical emergency? What to do

Journal corrects conclusion of Vioxx risk study

3-RXPublished June 27, 20063 min read

Key points

  • A critical study showing the heart attack and stroke risk of Merck and Co.'s now-withdrawn arthritis drug Vioxx contained statistical errors that incorrectly showed that the risk changes over time, The New England Journal of Medicine reported on Monday.
  • In fact, it is not possible to tell when the risk of heart attack or stroke shoot up, Journal editor Dr.
  • Last month, Merck said it was correcting one of the statistical methods used to analyze data from that key study, but said the change did not alter the results of that clinical trial.
  • The proportional hazards calculation in fact was not significant," Drazen said in a telephone interview.

A critical study showing the heart attack and stroke risk of Merck and Co.'s now-withdrawn arthritis drug Vioxx contained statistical errors that incorrectly showed that the risk changes over time, The New England Journal of Medicine reported on Monday.

The journal and the authors, including a team at Merck, are issuing a correction to the May 2005 study to show the risks do not, as originally shown, greatly increase after 18 months.

In fact, it is not possible to tell when the risk of heart attack or stroke shoot up, Journal editor Dr. Jeffrey Drazen said.

Merck withdrew Vioxx from the market in September of 2004 after a three-year study showed it doubled the risk of heart attack and strokes in patients who took it for at least 18 months.

Last month, Merck said it was correcting one of the statistical methods used to analyze data from that key study, but said the change did not alter the results of that clinical trial.

But Drazen said the mistake was significant enough to change some of the conclusions of the trial -- including the important 18-month cutoff.

"They found this mistake. It turned out they did the wrong math. The proportional hazards calculation in fact was not significant," Drazen said in a telephone interview.

"You couldn't make this argument that the hazards weren't proportionate over time. It meant a lot of their conclusions they had originally drawn no longer could be accepted."

The correction to the data from the study, called APPROVe, involves statistical and graphical methods used to assess whether the relative risk of Vioxx compared to placebo was constant or if it changed over time.

The statistical re-analysis of the trial was performed by Dr. Stephen W. Lagakos, professor of biostatistics at the Harvard School of Public Health in Boston. Not only did he find that the 18-month cut-off for cardiovascular risk was not statistically significant, he concludes: "One could not conclude from the data that a shorter course of rofecoxib is safe."

His analysis will be published in the July 13 issue of the Journal.

"Because of the mathematical errors, the editors allowed some statements in the original file which we no longer feel are supported by the weakened evidence," Drazen said.

Merck is facing more than 11,500 product liability lawsuits from people claiming to have been harmed by Vioxx, which earned $2.5 billion a year before it was withdrawn from the market.

Vioxx, known generically as rofecoxib, is in a class of drugs known as COX-2 inhibitors. These drugs were designed to be safer alternatives to aspirin, ibuprofen and other non-steroidal anti-inflammatory drugs or NSAIDs, which can cause stomach bleeding, which can sometimes be fatal.

Drazen defended the Journal's handling of the study, which has been criticized. "The papers always said that although it took 18 months for you to appreciate a difference in risk, it didn't mean you had to be exposed to the drugs for 18 months," Drazen said.

In other words, a patient could take Vioxx for three months, or six months, and not have the bad side effects until 18 months later.

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Filed underDrug Abuse
Cancer

EU to take another look at GSK breast cancer drug

Europe's drugs regulators will take another look at GlaxoSmithKline Plc's new breast cancer pill Tyverb after new data showed a small risk of higher liver enzymes during treatment with the drug. GSK, Europe's biggest…

2 min read

Drug Abuse

Study raises caution on new painkillers

A new class of painkillers that block a receptor called TRPV1 may interfere with brain functions such as learning and memory, a new study suggests. The experiments with rat brain found that the TRPV1 receptor…

4 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.